Thomas Moran, PhD of @MountSinaiNYC @IcahnMountSinai discusses advance novel biotherapies for treating cancer and coronavirus COVID-19.
#cancer #biotherapies #treatment #covid19 #coronavirus
__________
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year partnership to create new, fully human antibodies to treat and prevent various diseases including oncology and immunology.
The collaboration will also use the H2L2 Harbor Mice ® platform to produce monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).These fully human monoclonal antibodies may be used therapeutically for people exposed to the virus, or prophylactically for people at high risk of exposure, such as health care workers. The antibodies have the ability to stop the virus from spreading by preventing cell infection.
“We are pleased to be able to collaborate with HBM at this time and leverage our experience in therapeutic antibody generation as well as the viral expertise of the Microbiology Department with the unique human antibody producing mice from Harbour,” said Professor Thomas Moran, PhD, Director, Center for Therapeutic Antibody Development (CTAD) at Icahn School of Medicine at Mount Sinai.
“This is a unique collaboration that will give HBM access to Mount Sinai’s innovative research driven from its clinical practices. The agreement demonstrates HBM’s commitment to develop novel medicines and foster fast-track innovative research. We will push the boundaries of science and the development of new medicines that will ultimately translate into better treatments for patients,” said Jingsong Wang, MD, PhD, Founder, Chairman & Chief Executive Officer of HBM.
